AR102494A1 - METHODS TO TREAT EYE DISEASES - Google Patents

METHODS TO TREAT EYE DISEASES

Info

Publication number
AR102494A1
AR102494A1 ARP150103539A ARP150103539A AR102494A1 AR 102494 A1 AR102494 A1 AR 102494A1 AR P150103539 A ARP150103539 A AR P150103539A AR P150103539 A ARP150103539 A AR P150103539A AR 102494 A1 AR102494 A1 AR 102494A1
Authority
AR
Argentina
Prior art keywords
methods
eye diseases
treat eye
treatment
burden
Prior art date
Application number
ARP150103539A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR102494A1 publication Critical patent/AR102494A1/en

Links

Abstract

Método para reducir la carga del tratamiento para pacientes que padecen un trastorno neovascular intraocular, donde el método comprende administrar una cantidad terapéuticamente efectiva del antagonista del VEGF en una administración de la dosificación que incluye intervalos de tratamiento de 8 y/o 12 semanas.Method for reducing the burden of treatment for patients suffering from an intraocular neovascular disorder, where the method comprises administering a therapeutically effective amount of the VEGF antagonist in a dosage administration that includes treatment intervals of 8 and / or 12 weeks.

ARP150103539A 2014-11-07 2015-11-02 METHODS TO TREAT EYE DISEASES AR102494A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07

Publications (1)

Publication Number Publication Date
AR102494A1 true AR102494A1 (en) 2017-03-01

Family

ID=58688557

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150103539A AR102494A1 (en) 2014-11-07 2015-11-02 METHODS TO TREAT EYE DISEASES
ARP150103621A AR102572A1 (en) 2014-11-07 2015-11-06 FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP150103621A AR102572A1 (en) 2014-11-07 2015-11-06 FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

Country Status (1)

Country Link
AR (2) AR102494A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475597A (en) * 2017-04-26 2019-03-15 参天堂制药(株) Medical composite for eye

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475597A (en) * 2017-04-26 2019-03-15 参天堂制药(株) Medical composite for eye

Also Published As

Publication number Publication date
AR102572A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
CL2017001117A1 (en) Methods to treat eye diseases.
MX2023008368A (en) Methods of treating inflammatory conditions.
CY1122143T1 (en) DRUG COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR, AND OPTIONALLY A PI3K-ALPHA INHIBITOR
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
BR112016000546A2 (en) methods to treat or prevent eye conditions
EA201691872A1 (en) HETEROCYCLIC COMPOUNDS FOR APPLICATION IN THE TREATMENT OF PI3K-GAMMA-MEDIATED DISORDERS
BR112017002637A2 (en) methods to treat or prevent eye conditions
MX2021000538A (en) Sobetirome in the treatment of myelination diseases.
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
BR112017018964A2 (en) use of plinabulin and methods to treat brain tumor
EA201791199A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
EA201890891A1 (en) BIOMARKERS ASSOCIATED WITH INTERLEYKIN-33 DISEASES, AND THEIR APPLICATION
PH12017500933A1 (en) Sublingual administration of riluzole
PH12015501531B1 (en) Crenolanib for treating flt3 mutated proliferative disorders
CR20150637A (en) TREATMENT OF MIOPATIC AND NEURODEGENERATIVE DISEASES BY PROTEIN AGGREGATION THROUGH PARENTERAL ADMINISTRATION
MX2017006938A (en) Combination therapy for treatment of cancer.
PH12017500934A1 (en) Sublingual formulation of riluzole
EA201892265A1 (en) METHODS OF TREATMENT OF OPHTHALMIC DISEASES
MX2019009586A (en) Compositions and methods for treating disease associated with permeability of intestinal epithelium.
CL2019000625A1 (en) Fxr agonist combination.
EA201991175A1 (en) THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS
MD20170025A2 (en) Medical treatments based on anamorelin
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
AR102494A1 (en) METHODS TO TREAT EYE DISEASES
MX2022002947A (en) Avocatin b for the treatment of diseases and conditions.

Legal Events

Date Code Title Description
FB Suspension of granting procedure